317 related articles for article (PubMed ID: 32397231)
41. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome.
Yan W; Huang L
Int J Pharm; 2009 Feb; 368(1-2):56-62. PubMed ID: 18992312
[TBL] [Abstract][Full Text] [Related]
42. Optimization of lipid composition in cationic emulsion as in vitro and in vivo transfection agents.
Kim TW; Chung H; Kwon IC; Sung HC; Jeong SY
Pharm Res; 2001 Jan; 18(1):54-60. PubMed ID: 11336353
[TBL] [Abstract][Full Text] [Related]
43. Probing delivery of a lipid nanoparticle encapsulated self-amplifying mRNA vaccine using coherent Raman microscopy and multiphoton imaging.
Bera K; Rojas-Gómez RA; Mukherjee P; Snyder CE; Aksamitiene E; Alex A; Spillman DR; Marjanovic M; Shabana A; Johnson R; Hood SR; Boppart SA
Sci Rep; 2024 Feb; 14(1):4348. PubMed ID: 38388635
[TBL] [Abstract][Full Text] [Related]
44. Liposome-mediated DNA immunisation via the subcutaneous route.
Perrie Y; McNeil S; Vangala A
J Drug Target; 2003; 11(8-10):555-63. PubMed ID: 15203925
[TBL] [Abstract][Full Text] [Related]
45. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
Kim HK; Davaa E; Myung CS; Park JS
Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
[TBL] [Abstract][Full Text] [Related]
46. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
[TBL] [Abstract][Full Text] [Related]
47. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
[TBL] [Abstract][Full Text] [Related]
48. Incorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration.
Ziller A; Nogueira SS; Hühn E; Funari SS; Brezesinski G; Hartmann H; Sahin U; Haas H; Langguth P
Mol Pharm; 2018 Feb; 15(2):642-651. PubMed ID: 29232147
[TBL] [Abstract][Full Text] [Related]
49. Mannosylation of LNP Results in Improved Potency for Self-Amplifying RNA (SAM) Vaccines.
Goswami R; Chatzikleanthous D; Lou G; Giusti F; Bonci A; Taccone M; Brazzoli M; Gallorini S; Ferlenghi I; Berti F; O'Hagan DT; Pergola C; Baudner BC; Adamo R
ACS Infect Dis; 2019 Sep; 5(9):1546-1558. PubMed ID: 31290323
[TBL] [Abstract][Full Text] [Related]
50. Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin.
Zuidam NJ; Barenholz Y
Biochim Biophys Acta; 1997 Oct; 1329(2):211-22. PubMed ID: 9371413
[TBL] [Abstract][Full Text] [Related]
51. Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization.
Jiao X; Wang RY; Feng Z; Alter HJ; Shih JW
Hepatology; 2003 Feb; 37(2):452-60. PubMed ID: 12540796
[TBL] [Abstract][Full Text] [Related]
52. Formulation and in vitro and in vivo evaluation of a cationic emulsion as a vehicle for improving adenoviral gene transfer.
Kim SY; Lee SJ; Lim SJ
Int J Pharm; 2014 Nov; 475(1-2):49-59. PubMed ID: 25138255
[TBL] [Abstract][Full Text] [Related]
53. Inclusion of the helper lipid dioleoyl-phosphatidylethanolamine in solid lipid nanoparticles inhibits their transfection efficiency.
de Jesus MB; Radaic A; Hinrichs WL; Ferreira CV; de Paula E; Hoekstra D; Zuhorn IS
J Biomed Nanotechnol; 2014 Feb; 10(2):355-65. PubMed ID: 24738343
[TBL] [Abstract][Full Text] [Related]
54. Self-amplifying mRNA vaccines.
Brito LA; Kommareddy S; Maione D; Uematsu Y; Giovani C; Berlanda Scorza F; Otten GR; Yu D; Mandl CW; Mason PW; Dormitzer PR; Ulmer JB; Geall AJ
Adv Genet; 2015; 89():179-233. PubMed ID: 25620012
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens.
Maruggi G; Chiarot E; Giovani C; Buccato S; Bonacci S; Frigimelica E; Margarit I; Geall A; Bensi G; Maione D
Vaccine; 2017 Jan; 35(2):361-368. PubMed ID: 27939014
[TBL] [Abstract][Full Text] [Related]
56. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond.
Estapé Senti M; García Del Valle L; Schiffelers RM
Adv Drug Deliv Rev; 2024 Mar; 206():115190. PubMed ID: 38307296
[TBL] [Abstract][Full Text] [Related]
57. Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines.
Goswami R; O'Hagan DT; Adamo R; Baudner BC
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33572332
[TBL] [Abstract][Full Text] [Related]
58. Transdermal Delivery of Small Interfering RNA with Elastic Cationic Liposomes in Mice.
Hattori Y; Date M; Arai S; Kawano K; Yonemochi E; Maitani Y
J Pharm (Cairo); 2013; 2013():149695. PubMed ID: 26555966
[TBL] [Abstract][Full Text] [Related]
59. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes.
Campbell RB; Balasubramanian SV; Straubinger RM
J Pharm Sci; 2001 Aug; 90(8):1091-105. PubMed ID: 11536214
[TBL] [Abstract][Full Text] [Related]
60. Cationic liposomes formulated with a novel whole Leishmania lysate (WLL) as a vaccine for leishmaniasis in murine model.
Jafari I; Heravi Shargh V; Shahryari M; Abbasi A; Jaafari MR; Khamesipour A; Badiee A
Immunobiology; 2018; 223(6-7):493-500. PubMed ID: 29317110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
